Skip to content
Dose Brief
Menu

Provider review

Gide Health review

By · Updated

Gide names Beluga as a clinical-network partner and publishes state exclusions. Its advanced GLP-1 page has inconsistent drug naming, so the exact prescription needs confirmation before comparing prices.

Not rated. This review examines published program information; it is not a firsthand treatment review.

Visit Gide Health (opens in a new tab)Compare rated providers

At a glance

Semaglutide
GLP-1 injection from $209/month; semaglutide is named on that page. Drops from $149/month are a separate formulation.
Tirzepatide
Advanced GLP-1 injection from $299/month; current page does not reliably establish tirzepatide identity.
Availability
Terms exclude Mississippi, New Mexico and Louisiana; verify current availability for your state and product.
Treatment formats
Compounded GLP-1 injections and oral drops are advertised; advanced-product ingredient labeling needs clarification.

All-in renewal and supply terms require confirmation. Terms restrict refunds once services begin or a prescription reaches the pharmacy.

Three offers, not one interchangeable GLP-1

Gide lists a GLP-1 injection from $209 a month, an advanced injection from $299 and drops from $149. The standard injection page names semaglutide. The advanced page describes dual-pathway treatment but also repeats a semaglutide label. That inconsistency prevents us from treating the $299 figure as a verified tirzepatide quote. Obtain the drug, ingredients, dose and supplied amount in writing.

Who handles care and where?

Gide’s terms identify consultations and prescriptions through a network partner at Beluga Health and exclude Mississippi, New Mexico and Louisiana. Its contact page lists 440 N Barranca Avenue #1616, Covina, California. Check those state exclusions before comparing the quoted treatment prices. The reviewed pages still do not identify the pharmacy assigned to a particular patient.

Payment and refund limits

The terms describe fees at purchase and say purchases are final, with no refund after services commence or the prescription is sent to the pharmacy. The product pages do not establish a complete refill calendar, dose-related price schedule or cancellation notice period. Ask for those before authorizing a recurring charge, especially if considering the lower-priced oral route.

Our assessment

Gide has concrete service and geographic information, but inconsistent product copy makes prescription verification essential. General weight-loss percentages and promotional claims on its pages are not evidence for the exact compounded preparation. Oral drops should not be treated as interchangeable with injections or an approved oral brand. Stray references to another platform do not establish common ownership; this review evaluates Gide’s own published terms.

What stands out

  • Names a clinical-network relationship
  • Publishes specific excluded states

What to check

  • Advanced-product drug naming is inconsistent
  • Supply, renewal and cancellation details remain incomplete

Sources and review scope

Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.